Loading people...
Maha Katabi is a General Partner at Sofinnova Investments, a clinical-stage biopharmaceutical investment firm with $3.7 billion in assets under management, based in Menlo Park, California. Before joining the firm in 2019, she founded and served as Managing Partner at Oxalis Capital and was a Partner at Sectoral Asset Management, where she formed the private investment team. She holds a PhD in Pharmacology and a BSc in Biology from McGill University, and she is a CFA charterholder. Throughout her two-decade career, Katabi has directed investments and held board seats resulting in significant acquisitions, including Amplyx by Pfizer, Gyroscope by Novartis, Aiolos by GSK, and RayzeBio by Bristol Myers Squibb. She currently serves on the boards of ARTBIO, Marea, and Vera Therapeutics. Her ongoing investment strategy focuses on development-stage biopharmaceuticals addressing high unmet patient needs.
Maha Katabi stands as a prominent General Partner at Sofinnova Investments, a globally recognized venture capital firm renowned for its deep expertise in life sciences. In her pivotal role, Maha Katabi is instrumental in shaping the firm's investment strategy, leading deal sourcing, conducting rigorous due diligence, and providing invaluable strategic guidance to portfolio companies. Her leadership ensures that Sofinnova Investments continues to identify and back the most promising innovations poised to make a significant impact on human health.
At Sofinnova Investments, Maha Katabi's investment focus spans a broad spectrum within the life sciences and healthcare industries. She is particularly passionate about biotechnology, pharmaceuticals, medical devices, and emerging digital health solutions. Maha Katabi seeks out companies that are developing disruptive technologies, novel therapeutic approaches, and innovative diagnostics that address critical unmet medical needs. Her keen eye for scientific merit combined with a strong understanding of market dynamics allows her to pinpoint opportunities with high growth potential, from early-stage startups to more mature growth-stage enterprises.
Prior to her tenure as a General Partner at Sofinnova Investments, Maha Katabi built a robust career foundation marked by both scientific rigor and strategic business acumen. While specific details of her early career are not always publicly detailed, professionals in her position typically possess a strong background in scientific research, often holding advanced degrees in life sciences, medicine, or related fields. This foundational knowledge is frequently complemented by significant experience in the pharmaceutical or biotech industry, or prior roles in venture capital and private equity, where she would have honed her skills in evaluating complex scientific data and market opportunities. This blend of scientific understanding and investment expertise makes Maha Katabi a formidable force in the venture capital landscape.
Throughout her career, Maha Katabi has been associated with a track record of successful investments that have led to significant advancements in healthcare. While specific portfolio companies are often confidential or vary over time, her investment philosophy consistently centers on backing visionary founders and scientific teams dedicated to solving critical health challenges. Her strategic involvement helps guide these companies through crucial development phases, from clinical trials to market entry, ultimately aiming to bring life-changing therapies and technologies to patients worldwide. Maha Katabi's commitment to fostering innovation underscores Sofinnova Investments' mission to build enduring companies that redefine the future of health.
Maha Katabi is a General Partner at Sofinnova Investments, a leading venture capital firm specializing in life sciences and healthcare investments.
Maha Katabi primarily invests in companies within the life sciences and healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and digital health solutions.
Maha Katabi works as a General Partner at Sofinnova Investments, a prominent venture capital firm.
